natgillin/translations-raw huggingface dataset:
In vitro studies have shown that rucaparibinduced cytotoxicity involves inhibition of PARP enzymatic activity and the trapping of PARP-DNA complexes resulting in increased DNA damage, apoptosis, and cell death. 
Študije in vitro so pokazale, da z rukaparibom povzročena toksičnost vključuje zaviranje encimske dejavnosti PARP in preprečevanje sprostitve kompleksov PARP-DNA, kar povzroči povečane okvare DNA, apoptozo in celično smrt.
The progression-free interval to penultimate platinum therapy was 6-12 months in 39% of patients and > 12 months in 61%. 
Interval brez napredovanja bolezni za predzadnjim zdravljenjem s platino je bil 6-12 mesecev pri 39 % in > 12 mesecev pri 61 % bolnic.
Effect of other medicinal products on rucaparib 
Vpliv drugih zdravil na rukaparib
As inhibition of these transporters could increase metformin renal elimination and decrease liver uptake of metformin, caution is advised when metformin is co-administered with rucaparib. 
Ker bi zaviranje teh prenašalcev lahko povečalo izločanje metformina prek ledvic in zmanjšalo jetrni privzem metformina, je ob sočasnem dajanju metformina z rukaparibom priporočena previdnost.
In an animal reproduction study, administration of rucaparib to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 600 mg twice daily (see section 5.3). 
V študiji razmnoževanja pri živalih je dajanje rukapariba brejim podganam v obdobju organogeneze povzročilo embrio-fetalno toksičnost pri izpostavljenostih, nižjih od izpostavljenosti pri bolnicah, ki so prejemale priporočeni odmerek za človeka 600 mg dvakrat na dan (glejte poglavje 5.3).
Abdominal pain (combined terms abdominal pain, abdominal pain lower, abdominal pain upper) was reported in 40.1% of rucaparib treated patients, but was also very common (33%) in placebo patients, most likely associated with underlying disease. 
O bolečinah v trebuhu (skupno poimenovanje za bolečine v trebuhu, bolečine v spodnjem delu trebuha, bolečine v zgornjem delu trebuha) so poročali pri 40,1 % bolnic, ki so se zdravile z rukaparibom, zelo pogoste (33 %) pa so bile tudi pri bolnicah, zdravljenih s placebom, kar je najverjetneje povezano z osnovnimi boleznimi.
Interaction of rucaparib with other enzymes and transporter was evaluated in vitro. 
Medsebojno delovanje rukapariba z drugimi encimi in prenašalci so ocenjevali in vitro.
Rucaparib has been shown to decrease tumour growth in mouse xenograft models of human cancer with or without deficiencies in BRCA. 
Dokazali so, da rukaparib zmanjšuje rast tumorjev v ksenografskih modelih humanega raka pri miših z ali brez pomanjkanja BRCA.
The time of onset for adverse reactions of myelosuppression Grade 3 or higher was generally later in treatment (after 2 or more months). 
Do nastopa neželenih učinkov mielosupresije stopnje 3 ali višje je običajno prišlo v kasnejšem obdobju zdravljenja (po 2 ali več mesecih).
All patients had achieved a response (complete or partial) to their most recent platinum-based chemotherapy and their cancer antigen 125 (CA-125) was below the upper limit of normal (ULN). 
Vse bolnice so bile odzivne (popolnoma ali delno) na svojo zadnjo kemoterapijo na osnovi platine, njihov rakasti antigen 125 (CA-125) je bil pod zgornjo mejo normalne vrednosti (ULN).
No dose adjustment is considered necessary for co-administered medicinal products that are CYP2C19 substrates. 
Prilagoditve odmerka med sočasno uporabo zdravil, ki so substrati CYP2C19, niso potrebne.
For risk mitigation and management, see section 4.4. 
Za ukrepe za izogibanje tveganju in za obvladovanje tveganja glejte poglavje 4.4.
Rubraca can be used as maintenance therapy immediately after a course of chemotherapy that has caused the tumour to shrink. 
Zdravilo Rubraca je mogoče uporabljati kot vzdrževalno zdravilo takoj po kemoterapiji, ki je povzročila krčenje tumorja.
The proportion of platinum-sensitive patients with gBRCA and sBRCA mutations was comparable to the primary efficacy population at n=66 (83.5%) and n=13 (16.5%) respectively. 
občutljivim na platino, z mutacijami gBRCA in sBRCA je bil primerljiv s primarno populacijo študije učinkovitosti z n = 66 (83,5 %) in n = 13 (16,5 %).
Take your next dose at your regular time. 
Svoj naslednji odmerek vzemite ob predvidenem času.
The mean age was 61 years (range: 36 to 85); most of the patients were white (80%); and all had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 
Povprečna starost je bila 61 let (razpon: 36-85); večina bolnic je pripadala beli rasi (80 %); vse pa so imele stanje zmogljivosti po Eastern Cooperative Oncology Group (ECOG) 0 ali 1.
The duration of therapy with rucaparib in patients who developed MDS/AML varied from less than 1 month to approximately 28 months. 
Pri bolnicah, ki so zbolele za MDS/AML, je zdravljenje z rukaparibom trajalo od manj kot 1 meseca do približno 28 mesecev.
Contents of the pack and other information What Rubraca contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Rubraca
Rubraca must not be used during breast-feeding. 
Zdravila Rubraca se med dojenjem ne sme uporabljati.
Pyrexia a MDS/AML rate is based on overall total patient population of 1321 who have received one dose of oral rucaparib. 
Občasni pireksija a Stopnja MDS/AML temelji na skupni populaciji 1321 bolnic, ki so prejele en peroralni odmerek rukapariba.
Events related to increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were observed in 38% (all grades) and 11% (≥ CTCAE Grade 3) of patients. 
Dogodke, povezane z zvišanimi ravnmi alanin-aminotransferaze (ALT) in aspartat-aminotransferaze (AST), so opažali pri 38 % (vse stopnje) in 11 % (≥ stopnja CTCAE 3) bolnic.
For the platinum-resistant population (N=20), ORR by investigator review was 35.0% (95% CI [15.4, 59.2], with a complete response rate of 5.0%, and a partial response rate of 30.0%. 
Za populacijo, odporno na platino (N=20), je bila stopnja objektivnega odziva po pregledu raziskovalca 35,0 % (95-% IZ [15,4; 59,2], s stopnjo popolnega odziva 5,0 % in stopnjo delnega odziva 30,0 %.
Your doctor may test your bone marrow to check for any problems. 
Zdravnik bo pri vas morda opravil preiskavo kostnega mozga, da bo raziskal morebitne težave.
a The median duration of response is determined from the patients who had an objective tumour response according to RECIST guidelines, following treatment with rucaparib. 
a Mediano trajanje odziva je bilo določeno glede na bolnice, ki so imele po zdravljenju z rukaparibom objektivni odziv tumorja glede na smernice RECIST.
Medicinal product interactions 
Medsebojno delovanje zdravil
Based on population PK analysis, no clinically significant relationships were identified between predicted steady-state exposure and patient's age, race, and body weight. 
Na podlagi populacijske farmakokinetične analize niso ugotovili klinično pomembnih razmerij med predvideno izpostavljenostjo v stanju dinamičnega ravnovesja in bolničino starostjo, raso in telesno maso.
At clinical exposures, rucaparib did not inhibit bile salt export pump (BSEP), OATP1B1, OATP1B3, OAT1 and OAT3. 
Pri kliničnih izpostavljenostih rukaparib ni zaviral eksportne črpalke žolčnih soli (BSEP - bile salt export pump), OATP1B1, OATP1B3, OAT1 in OAT3.
Complete blood count testing prior to starting treatment with Rubraca, and monthly thereafter, is advised. 
Preiskavo s celotno krvno sliko je priporočljivo opraviti pred zdravljenjem z zdravilom Rubraca, nato pa vsak mesec.
Rubraca is an anti-cancer medicine, also known as a ‘PARP (poly adenosine diphosphate-ribose polymerase) inhibitor'. 
Zdravilo Rubraca je zdravilo proti raku, imenovano tudi „zaviralec PARP (poli [adenozin-difosfat-riboza] polimeraza)“.
What Rubraca is and what it is used for What Rubraca is and how it works 
Kaj je zdravilo Rubraca in za kaj ga uporabljamo Kaj je zdravilo Rubraca in kako deluje
This is because it is not known if rucaparib passes into breast milk. 
Ni namreč znano, ali rukaparib prehaja v materino mleko ali ne.
Other medicines and Rubraca 
Druga zdravila in zdravilo Rubraca
Adverse reactions leading to permanent discontinuation occurred in 10% of patients, with thrombocytopenia, nausea, anaemia, and fatigue/asthenia being the most frequent adverse reactions leading to permanent discontinuation. 
Neželeni učinki, ki so vodili do trajne prekinitve, so se pojavili pri 10 % bolnic, trombocitopenija, navzea, anemija in utrujenost/astenija pa so bili najpogostejši neželeni učinki, ki so vodili do trajne prekinitve.
For the maintenance treatment, patients should start the maintenance treatment with Rubraca no later than 8 weeks after completion of their final dose of the platinum containing regimen. 
Pri vzdrževalnem zdravljenju morajo bolnice vzdrževalno zdravljenje z zdravilom Rubraca začeti najkasneje 8 tednov po zadnjem odmerku režima zdravljenja s platino.
In vitro, M324 was at least 30 fold less potent than rucaparib against PARP-1, PARP-2, and PARP-3. 
In vitro je bil M324 vsaj 30-krat manj učinkovit od rukapariba proti PARP-1,
Caution should be exercised and additional International Normalised Ratio (INR) monitoring with co-administration of warfarin and therapeutic drug level monitoring of phenytoin should be considered, if used concomitantly with rucaparib. 
Treba je razmisliti o dodatnem spremljanju vrednosti INR (internacionalno normalizirano razmerje) pri sočasnem dejanju varfarina in o spremljanju terapevtskih ravni fenitoina, če je uporabljen sočasno z rukaparibom.
Rucaparib accounted for 44.9% and 94.9% of radioactivity in urine and faeces, respectively; while M324 accounted for 50.0% and 5.1% of radioactivity in urine and faeces, respectively. 
Rukaparib je predstavljal 44,9 % radioaktivnosti v urinu in 94,9 % v blatu, medtem ko je M324 predstavljal 50,0 % radioaktivnosti v urinu in 5,1 % v blatu.
Patients with germline (g)BRCA (n=88, 83.0%) or somatic (s)BRCA (n=18, 17.0%) mutations were included. 
(g)BRCA (n = 88, 83,0 %) ali somatskimi mutacijami (s)BRCA (n = 18, 17,0 %).
If you stop taking Rubraca 
Če ste prenehali jemati zdravilo Rubraca
No effects on male and female fertility were observed in 3-month general toxicology studies in rats and dogs at exposures of 0.09 to 0.3 times the human AUC at the recommended dose. 
V 3-mesečni študiji splošne toksičnosti pri podganah in psih niso opazili učinkov na plodnost samcev in samic pri izpostavljenostih, ki so obsegale od 0,09- do 0,3-kratnik vrednosti AUC pri človeku ob priporočenem odmerku.
Rubraca can also be used if your cancer has progressed after chemotherapy has been used and you have an abnormality of the BRCA gene. 
Zdravilo Rubraca je mogoče uporabljati tudi, če je rak po kemoterapiji napredoval in če imate nenormalnost v genu BRCA.
Rucaparib was not mutagenic in a bacterial reverse mutation (Ames) assay. 
Rukaparib pri preizkusu reverzne mutacije pri bakterijah (Amesov test) ni bil mutagen.
Haematological adverse reactions of all CTCAE Grades of anaemia, thrombocytopenia and neutropenia were reported in 42%, 26% and 16% of patients respectively. 
O hematoloških neželenih učinkih vseh stopenj po CTCAE, anemiji, trombocitopeniji in nevtropeniji, so poročali pri 42 %, 26 % oz. 16 % bolnic.
Talk to your doctor if you feel sick (nauseous), have been sick (vomiting) or you have had diarrhoea. 
Pogovorite se z zdravnikom, če vam je slabo ali bruhate ali če ste imeli drisko.
• medicines to lower blood cholesterol levels- such as rosuvastatin 
• zdravila za zniževanje ravni holesterola v krvi - npr. rosuvastatin,
Gastrointestinal toxicities (nausea and vomiting) are frequently reported with rucaparib, are generally low grade (CTCAE Grade 1 or 2), and may be managed with dose reduction (refer to Table 1) or interruption. 
Pri zdravljenju z rukaparibom pogosto poročajo o gastrointestinalni toksičnosti (navzei in bruhanju), ki je običajno nizke stopnje (stopnje 1 ali 2 po CTCAE) in jo je mogoče obvladovati z zmanjšanjem odmerka (glejte Preglednico 1) ali s prekinitvijo zdravljenja.
The ORR, by independent radiology review for the platinum-sensitive population, was 42/79, 53.2% (95% CI [41.6-64.5]). 
Stopnja objektivnega odziva po pregledu neodvisnega radiologa za populacijo, občutljivo na platino, je bila 42/79, 53,2 % (95-% IZ [41,6-64,5]).
In vitro, rucaparib was shown to be a substrate of P-gp and BCRP. 
In vitro se je izkazalo, da je rukaparib substrat za P-gp in BCRP.
A potential risk cannot be ruled out based on the safety margin observed. 
Glede na upoštevane varnostne omejitve potencialnega tveganja ni mogoče izključiti.
Adverse reactions may be managed through dose interruptions and/or dose reductions for moderate to severe reactions (i.e. CTCAE Grade 3 or 4) such as neutropenia, anaemia and thrombocytopenia. 
Neželene učinke je mogoče obvladovati s prekinitvami odmerjanja in /ali z zmanjšanjem odmerkov v primeru zmernih do hudih učinkov (tj. stopnje 3 ali 4 po CTCAE), ko so npr. nevtropenija, anemija in trombocitopenija.
This is because Rubraca can cause low blood counts of: 
To je nujno zato, ker zdravilo Rubraca lahko povzroči nizko število naslednjih krvnih celic:
A pregnancy test before initiating treatment is recommended in women of reproductive potential. 
Pred uvedbo zdravljenja se pri ženskah v rodni dobi priporoča test nosečnosti.
Frequency of all CTCAE grades Frequency of CTCAE grade 3 and above 
Pogostnost stopnje 3 in višjih po CTCAE
Limited data are available for patients with moderate or severe hepatic impairment (see section 4.2). 
Za bolnice z zmerno ali hudo okvaro jeter so na voljo omejeni podatki (glejte poglavje 4.2).
PFS assessed by blinded independent radiology review (BIR) was a key secondary efficacy outcome. 
Ključne sekundarne rezultate učinkovitosti predstavlja PFS po neodvisni slepi radiološki oceni (BIR).
Effects of rucaparib on other medicinal products 
Vpliv rukapariba na druga zdravila
Concentration-QTcF prolongation analysis was conducted using data from 54 patients with a solid tumour administered continuous rucaparib at doses ranging from 40 mg once daily to 840 mg twice daily (1.4 times the approved recommended dose). 
Analiza razmerja koncentracija-podaljšanje intervala QTcF je bila opravljena s pomočjo podatkov 54 bolnic s čvrstim tumorjem, ki so jim dajali stalne odmerke rukapariba od 40 mg enkrat na dan do 840 mg dvakrat na dan (1,4-kratnik odobrenega priporočenega odmerka).
Although in vitro rucaparib metabolism mediated by CYP3A4 was slow, a significant contribution of CYP3A4 in vivo cannot be excluded. 
Čeprav je bila presnova rukapariba in vitro prek CYP3A4 počasna, ni mogoče izključiti pomembnega prispevka CYP3A4 in vivo.
No adjustment is recommended to the starting dose for elderly patients (≥ 65 years of age) (see sections 4.8 and 5.2). 
Prilagoditve začetnega odmerka za starejše bolnice (≥ 65 let) niso priporočene (glejte poglavji 4.8 in
• feeling tired 
Pogosti utrujenostc
Antiemetics, such as 5-HT3 antagonists, dexamethasone, aprepitant and fosaprepitant, can be used as treatment for nausea/vomiting and may also be considered for prophylactic (i.e., preventative) use prior to starting Rubraca. 
Za zdravljenje navzee/bruhanja je mogoče uporabiti tudi antiemetike, kot so npr. antagonisti 5-HT3, deksametazon, aprepitant in fosaprepitant; o teh zdravilih pa je mogoče razmišljati tudi v smislu profilakse (tj. preventivnega zdravljenja) pred uvedbo zdravljenja z zdravilom Rubraca.
Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Vomiting and nausea were reported in 42% and 77% of patients, respectively and were generally low grade (CTCAE Grade 1 to 3). 
O bruhanju so poročali pri 42 %, o navzei pa pri 77 % bolnic, običajno sta bila nizke stopnje (stopnja od 1 do 3 po CTCAE).
Intravenous administration of rucaparib in the rat and dog induced cardiac effects at a high Cmax (5.4 to 7.3-fold higher than patients), but not at a lower Cmax (1.3 to 3.8-fold higher than patients). 
Intravensko dajanje rukapariba podganam in psom je povzročilo učinke na srce pri visokih vrednostih Cmax (5,4- do 7,3-krat večje kot pri bolnicah), ne pa pri nizkih vrednostih Cmax (1,3- do 3,8- krat večje kot pri bolnicah).
No interaction with MRP2 or MRP3 was observed in vitro at the clinical exposure of rucaparib, however, mild bi-phasic activation and inhibition of MRP2 and concentration dependent inhibition of MRP3 were observed at concentrations higher than the observed plasma Cmax of rucaparib. 
In vitro niso opazili nobenega medsebojnega delovanja z MRP2 ali z MRP3 pri klinični izpostavljenosti rukaparibu, opazili pa so blago bifazno aktivacijo in zaviranje MRP2 ter od koncentracije odvisno zaviranje MRP3 pri koncentracijah, višjih od ugotovljene plazemske vrednosti Cmax rukapariba.
Based on its mechanism of action and preclinical data, rucaparib may cause fetal harm when administered to a pregnant woman. 
Glede na mehanizem delovanja in predklinične podatke lahko rukaparib škoduje plodu, če se uporablja pri nosečnici.
Increased alanine aminotransferase, Increased aspartate aminotransferase 
Pogosti zvišane ravni alaninaminotransferaze, zvišane ravni aspartat-aminotransferaze
Randomisation was stratified by best response to last platinum therapy (complete or partial), time to progression following the penultimate platinum therapy (6 to ≤ 12 months and > 12 
Randomizacija je bila stratificirana glede na najboljši odziv (popolni ali delni) na zadnjo terapijo na osnovi platine, čas do napredovanja bolezni po predzadnjem zdravljenju s platino (od 6 do ≤ 12
Interrupt rucaparib until values return to Grade ≤ 2; then resume rucaparib with a dose reduction and monitor LFTs weekly for 3 weeks 
Zdravljenje z rukaparibom prekinite, dokler se vrednosti ne vrnejo na stopnjo ≤ 2; nato nadaljujte z dajanjem rukapariba v zmanjšanem odmerku in tedensko 3 tedne spremljajte izvide jetrnih preiskav.
Myelodysplastic syndrome/Acute myeloid leukaemia MDS/AML are serious adverse reactions that occur uncommonly (0.5%) in patients on treatment and during the 28 day safety follow up, and commonly (1.3%) for all patients including during the long term safety follow up (rate is calculated based on overall safety population of 1321 patients exposed to at least one dose of oral rucaparib in all clinical studies). 
MDS/AML sta resna neželena učinka, ki se pojavljata občasno (0,5 %) pri bolnicah med zdravljenjem in v obdobju 28-dnevnega spremljanja varnosti in pogosto (1,3 %) pri vseh bolnicah, vključno z dolgoročnim spremljanjem varnosti (stopnja je izračunana na podlagi skupne populacije za vrednotenje varnosti zdravila, ki je zajemala 1321 bolnic, izpostavljenih najmanj enemu peroralnemu odmerku rukapariba v vseh kliničnih študijah).
Caution should be used when rucaparib is co-administered with UGT1A1 substrates (i.e. irinotecan) to patients with UGT1A1*28 (poor metabolizer) due to a possible increase in the exposure of SN-38 (the active metabolite of irinotecan) and associated toxicities. 
Pri sočasnem dajanju rukapariba in substratov UGT1A1 (npr. irinotekana) bolnicam z UGT1A1*28 (slabe presnavljalke) je potrebna previdnost zaradi možnega povečanja izpostavljenosti SN-38 (aktivnemu presnovku irinotekana) in s tem povezanih toksičnosti.
Platinum-sensitive patients had received 2 (n=47, 59.5%), 3 (n=28, 35.4%), or > 3 (n=4, 5.1%) prior lines of platinumbased chemotherapy. 
Bolnice z rakom, občutljivim na platino, so prejele 2 (n = 47, 59,5 %), 3 (n = 28, 35,4 %) ali > 3 (n = 4, 5,1 %) predhodne cikle kemoterapije na osnovi platine.
Most patients could continue rucaparib with or without treatment modification without recurrence of 
Večina bolnic je z zdravljenjem z rukaparibom z ali brez prilagoditve zdravljenja lahko nadaljevala brez ponovnega pojava nenormalnosti jetrnih preiskav ≥ stopnje 3.
Interactions between rucaparib and oral contraceptives have not been studied. 
Medsebojnega delovanja rukapariba in peroralnih kontraceptivov niso proučevali.
282 days (95% CI [218-335]), and the median overall survival was 18.8 months (95% CI [12.9-NA]). 
Mediano preživetje brez napredovanja je bilo 282 dni (95-% IZ [218-335]), mediano celokupno preživetje pa 18,8 mesecev (95-% IZ [12,9-NA]).
• anticoagulant medicines which helps the blood flow freely, such as warfarin 
• zdravila proti strjevanju krvi (antikoagulante), ki omogočajo neoviran pretok krvi - npr. varfarin,
Each bottle contains 60 film-coated tablets. 
Ena plastenka vsebuje 60 filmsko obloženih tablet.
Then take your next dose at the usual time. 
Nato vzemite naslednji odmerek ob predvidenem času.
During treatment with rucaparib, events of myelosuppression (anaemia, neutropenia, thrombocytopenia) may be observed and are typically first observed after 8-10 weeks of treatment with rucaparib. 
Med zdravljenjem z rukaparibom se lahko pojavijo učinki mielosupresije (anemija, nevtropenija, trombocitopenija), ki se običajno prvikrat pojavijo po 8-10 tednih zdravljenja z rukaparibom.
Hypercholesterolaemiab, Dehydration 
Pogosti hiperholesterolemijab, dehidracija
In an embryo-foetal development study in rats, rucaparib was associated with post-implantation loss at exposures of approximately 0.04 times the human AUC at the recommended dose. 
V študijah embrio-fetalnega razvoja pri podganah je bil rukaparib povezan z izgubo ploda po ugnezdenju pri izpostavljenostih, ki so približno ustrezale 0,04-kratniku vrednosti AUC pri človeku ob priporočenem odmerku.
This medicinal product has been authorised under a so-called ‘conditional approval' scheme. 
Zdravilo je pridobilo tako imenovano "pogojno dovoljenje za promet".
• keep out of direct sunlight and not use sunbeds while you are taking Rubraca 
• med jemanjem zdravila Rubraca izogibati neposredni sončni svetlobi in ne smete uporabljati solarijev.
Rubraca is used to treat a type of cancer of the ovary. 
Zdravilo Rubraca uporabljamo za zdravljenje vrste raka jajčnikov.
Plasma exposures of rucaparib, as measured by Cmax and AUC, were approximately dose proportional at evaluated doses (40 to 500 mg daily, 240 to 840 mg twice a day). 
Plazemske izpostavljenosti rukaparibu, merjene s Cmax in AUC, so bile za ocenjene odmerke (40 do 500 mg na dan, 240 do 840 mg dvakrat na dan) približno sorazmerne z odmerkom.
In patients with cancer following a high-fat meal, the Cmax increased by 20%, the AUC0-24h increased by 38%, and the Tmax was delayed by 2.5 hours, as compared with dosing under fasted conditions. 
Pri bolnicah z rakom je po obroku z veliko vsebnostjo maščob vrednost Cmax narasla za 20 %, vrednost AUC0-24h za 38 %, vrednost Tmax se je podaljšala za 2,5 ure v primerjavi z odmerjanjem na tešče.
Patients should be advised to use effective contraception during treatment and for 6 months following the last dose of rucaparib. 
Bolnicam je treba svetovati uporabo zanesljive kontracepcije med zdravljenjem in še 6 mesecev po prejemu zadnjega odmerka rukapariba.
• before treatment with Rubraca 
• pred zdravljenjem z zdravilom Rubraca
Management of Treatment-emergent AST/ ALT Elevations Grade of AST/ALT Elevation 
Uravnavanje zvišanj vrednost AST/ALT, ki se pojavijo med zdravljenjem Stopnja zvišanja vrednosti AST/ALT
Photosensitivity was reported in 13% of patients as low grade skin reactions (CTCAE Grade 1 or 2), and by 2 (0.2%) patients as ≥ CTCAE Grade 3 reaction. 
O preobčutljivosti na svetlobo so poročali pri 13 % bolnic kot o kožnem učinku nizke stopnje (stopnja CTCAE 1 ali 2), pri 2 (0,2 %) bolnicah pa kot o učinku stopnje CTCAE 3.
• If you forget to take a dose, skip the missed dose. 
• Če ste pozabili vzeti odmerek, ga preskočite.
Rucaparib has been shown to have in vitro and in vivo anti-tumour activity in BRCA mutant cell lines through a mechanism known as synthetic lethality, whereby the loss of two DNA repair pathways is required for cell death. 
Ugotovljeno je bilo, da rukaparib zavira tumorsko dejavnost in vitro in in vivo v mutantskih celičnih linijah BRCA prek mehanizma, imenovanega sintezna smrtnost, pri katerem je potrebna izguba dveh poti popravila DNA, da pride do celične smrti.
Rucaparib Placebo 
Placebo Rukaparib